1995-96
Thrombolysis and Thrombin Inhibition in Myocardial
Infarction (TIMI 9B), Ciba-Geigy Pharmaceuticals, Co-Principal
Investigator
1995-97
A phase II, placebo-controlled, multicenter study
of TLC C-53 as an adjunct to thrombolytic therapy in patients
with acute myocardial infarction (Liposomal intervention
followed by thrombolysis, LIFT) The Liposome Company, Principal
Investigator
1995-97
Global Cutting Balloon Randomized Trial, Interventional
Vascular Technologies, Co-Principal Investigator
1995-97
ReoPro in Acute myocardial infarction and Primary
PTCA Organization and Randomized Trial (RAPPORT), Eli Lilly,
Co. Co-Principal Investigator
1995
Doppler Endpoint Stenting International Investigation
(DESTINI), Cardiometrics Corp., Co-Principal Investigator
1997-98
Aspirin/Ticlopidine vs. Low molecular weight
heparin/Aspirin/ticlopidine high risk Stent Trial (ATLAST),
Rhône-Poulenc Rorer, Principal Investigator
1997-99
Treat Angina with Aggrastat and Determine Cost
of Therapy with Invasive or Conservative Strategies (TACTICS-TIMI
18), Merck & Co., Inc. Principal Investigator
1997-99
Diagnosis of Acute Myocardial Infarction by Measurement
of Circulating Monocyte-Platelet Aggregates. CompuCyte Corp.,
Principal Investigator
1997-98
Measurement of Platelet Activation by P-Selectin
Profile Centocor Diagnostics of PA, Inc., Principal Investigator
1997-present
Predication of Cardiac Events after Percutaneous
Coronary Intervention by Measurement of Circulating Monocyte-Platelet
Aggregates, CompuCyte Corp., Principal Investigator
1998-present
A Study to Assess the Equivalence of the Accumetrics
Rapid Platelet Function Assay (RPFA) in patients undergoing
interventional cardiac procedures to: 1) a GPIIb-IIIa receptor
blockade assay using I125 Abciximab and 2) platelet aggregometry
using a Chronolog aggregometer for detection of platelet
aggregation, Accumetrics Inc, Co-Principal Investigator
1998-present
In Vitro Effects of GPIIb-IIIa Inhibitors On
Platelet Procoagulant Ability in Whole Blood, Centocor,
Inc, Principal Investigator
1998-present
In
Vitro Effects of GPIIb-IIIa Inhibitors On Monocyte-Platelet
Interactions in Whole Blood, Centocor, Inc, Principal Investigator
1999-present
The Effects of Retaplase and Alteplase on Platelet
Function in Acute Myocardial Infarction, Centocor, Inc,
Principal Investigator
1999-present
In Vivo Effects of Abciximab on Platelet and
Leukocyte Activation, Leukocyte-Platelet Aggregation, Platelet
Procoagulant Activity, and Platelet-Derived Microparticles
in Patients with Unstable Angina/Non-Q-Wave Myocardial Infarction:
A Case-Control Study, Centocor, Inc, Principal Investigator
1999-present
Diagnosis of Stroke by Measurement of Circulating
Monocyte-Platelet Aggregates. CompuCyte Corp., Principal
Investigator,
2000-present
In Vivo Effects of Abciximab on Platelet-Endothelial
Cell Adhesion in Patients with Unstable Angina/Non-Q-Wave
Myocardial Infarction: A Case-Control Study, Centocor, Inc,
2000-present
The Effect of LDL Apheresis on Platelet and Leukocyte
Activation, Leukocyte-Platelet Aggregation, Kaneka American/Parke
Davis Pharmaceuticals, Principal Investigator (Collaboration
with Andrew P. Selwyn, M.D., Brigham and Women's Hospital),
2000-present
A Blinded, Randomized Comparative Trial of Dalteparin
versus Unfractionated Heparin in Conjunction with Abciximab
Platelet GP IIb/IIIa Inhibition During and Following Elective
Percutaneous Coronary Intervention (Platelet function core
laboratory). Principal Investigator, Pharmacia & Upjohn
2000-present
Placebo Controlled Randomized Administration
of Reduced Dose Abciximab Prior to Percutaneous Coronary
Intervention in Patients Receiving Intravenous Abciximab
Infusion Following Pharmacologic Reperfusion of Acute Myocardial
Infarction. (Platelet function core laboratory). Principal
Investigator, Centocor, Inc.
2000-present
In Vivo Effects of Fibrinolytic Therapy with
Concomitant GPIIb-IIIa Inhibition on Platelet and Leukocyte
Activation and Leukocyte-Platelet Aggregation. A Substudy
of TIMI 22, 23, and 24 (FASTER, INTEGRITI, ENTIRE), Principal
Investigator, Merck & Co and CompuCyte Corp.
2000-present
In Vivo Effects of Aggrastat and TNK-tPA on Platelet
and Leukocyte Activation and Platelet-Leukocyte Aggregation.
A Substudy of the Fibrinolytics and Aggrastat with ST Elevation
Resolution Trial (FASTER), Principal Investigator, Merck
& Co.
2000-present
Recombinant P-Selectin Glycoprotein Ligand Ig
in Combination with Thrombolytic Therapy in Acute Myocardial
Infarction. Principal Investigator, Wyeth-Ayerst.
